Original Paper

An Experience of Hepatopancreatoduodenectomy
in Patients with Hepato-Biliary Malignancies

Atsushi Nanashima, MD, Toshiya Nagasaki, MD, Yorihisa Sumida, MD,
Takafumi Abo, MD, Syuuichi Tobinaga, MD, Hiroaki Takeshita, MD,
Takashi Nonaka, MD, Shigekazu Hidaka, MD, Terumitsu Sawai, MD,
Toru Yasutake, MD, Takeshi Nagayasu, MD

Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki
University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki
852-8501, Japan

Running title: HPD in hepatobiliary malignancy

Corresponding and reprint requests to: Atsushi Nanashima, M.D.
Division of Surgical Oncology, Department of Translational Medical Sciences,
Nagasaki University Graduate School of Biomedical Sciences,
1-7-1 Sakamoto, Nagasaki 852-8501, JAPAN
Tel.: +81-95-819-7304, Fax: +81-95-819-7306
E-mail: a-nanasm@net.nagasaki-u.ac.jp
ABSTRACT

Background/Aims: In the advanced stage of hepatobiliary malignancies, concurrent hepatopancreatoduodenectomy (HPD) is necessary to accomplish curative resection, even though high rates of morbidity and mortality still remain. Methodology: We examined the surgical records and outcome in 11 patients undergoing HPD. Results: In 11 patients, diseases included bile duct carcinomas in 7 patients, gallbladder carcinomas in 3, and ampullar carcinoma in one. Hemi-hepatectomy with resection of the caudate lobe was performed in 8 patients and resection of segment 4 and 5 of the liver in two. Pancreatoduodenectomy (PD) was performed in 3 patients and pylorus preserving PD in 8. Curative resection was accomplished in 8 patients. Two patients underwent adjuvant photodynamic therapy because of a cancer-positive margin. Morbidity rate was 36% but no hospital deaths were reported. The tumor recurrence rate was 73% and 8 patients died of cancer. Patient prognosis of gallbladder cancers (12±1 months) tended to be shorter than in patients with bile duct cancers (19±11 months) (p=0.15). Three patients with bile duct cancers survived without tumor relapse over 12 months. Conclusions: Complete surgical resection (R0) by HPD could be safely performed for diseases of the hepatobiliary malignancies, which achieved longer survival in some patients.

KEYWORDS: hepatectomy, pancreatoduodenectomy, biliary malignancy

ABBREVIATIONS: Bile duct carcinomas (BDC), gallbladder carcinomas (GBC), hepatopancreatoduodenectomy (HPD), pancreatoduodenectomy (PD)
INTRODUCTION

In recent years, surgical resection is the only curable treatment for advanced biliary malignancies, and a concurrent hepatopancreatoduodenectomy (HPD) is often necessary to accomplish complete (R0) resections (1-4). The resectability of hepatobiliary malignancies has markedly improved with the improvement of operative techniques (5, 6). However, physical stress in patients is severe and postoperative morbidity and mortality rate are still not low (7, 8). Therefore, the indication for HPD should be carefully decided. In the present report, we examined our results of HPD in patients with biliary malignancies at a Japanese single cancer institute and discuss the clinical status and problems.

METHODOLOGY

Patients

We analyzed 11 patients with biliary malignancies who underwent surgical resection in the Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences (NUGSBS) between 1996 and 2006. The study design was approved by the Human Ethics Review Board of our institution. Informed consent for data collection was obtained by each patient during this period. Anesthetic and patient data were retrieved in the NUGSBS database. Tumor stage and curability was followed by the Classification of Biliary Tract Carcinoma by the Japanese Society of Biliary Surgery (9).
Operative indications, procedures and follow-up

The indication of HPD at our institute was described as follows: 1) malignant biliary diseases needing hepatic resection, which extends to duodenum and pancreatic head, 2) biliary malignancies with remarkably metastatic lymph node at peri-pancreatic head, 3) cases where cancer lesions could be completely (= radically) resected by HPD without liver metastasis, peritoneal dissemination, para-aortic lymph node metastasis or more distant metastasis, and 4) good general conditions and liver functions but border of patient age was not decided.

In liver resection, the volume to be resected is estimated preoperatively based on the results of indocyanine green retention rate at 15 minutes (ICGR15) using Takasaki’s formula (10). The liver volume, excluding tumor volume (cm$^3$), is measured by CT volumetry (11). We routinely clamped the hepatoduodenal ligament to occlude total inflow to the liver during transection (Pringle’s maneuver). We also routinely used the forceps fracture method (12) and an ultrasonic dissector (USU MH-207, Olympus, Tokyo, Japan) for the transection of liver parenchyma. In pancreatic resection, pancreatoduodenectomy (PD) was usually performed in HPD. Pancreatic functions were not considered as operative indications.

After discharge from hospital, the patient status, laboratory data, and disease recurrence were checked every 2 to 3 months.

RESULTS
Patients included 6 men and 5 women with a mean age of 67.3 ± 8.0 years (± SD, range, 54-77 years) (Table 1). Diseases included bile duct carcinomas in 7 patients, gallbladder carcinomas in 3, and ampullar carcinoma in 1 patient. Reasons for liver resection were direct hepatic invasion of gallbladder carcinoma in 3 patients, extended hilar bile duct carcinoma in 7 and superficially wide extension to hilar bile duct of the ampullar carcinoma in 1 patient. Reasons for pancreatic resection included lymph node metastasis involving pancreatic head of gallbladder carcinoma in 3 patients, superficially wide extension of bile duct carcinoma to lower bile duct in the pancreas head in 7 patients, and advanced ampullar carcinoma in 1 patient.

Right hepatectomy with resection of caudate lobe was performed in 5 patients, left hepatectomy with resection of caudate lobe in 3, and partial resection of segment 4 and 5 of the liver in 2 patients. PD was performed in 3 patients and pylorus preserving PD in 8 patients. All patients underwent loco-regional lymphadenectomy (Table 2). The operation time ranged between 494 and 984 minutes (mean was 703 ± 144 minutes) and blood loss ranged between 910 and 2920 minutes (mean was 1778 ± 654 mL). Tumor stage with stage IV was observed in 8 patients (73%). Curability A and B was accomplished in 8 patients and 3 had curability C due to positive cancer margin at hepatic cut end, which caused superficial extension of carcinoma along the intra-epithelium. Two underwent adjuvant photodynamic therapy after surgery in patients with curability C.

Postoperative complications were observed in 4 patients (36%) but no hospital death. These complications subsided within a few weeks (Table 3). Duration of hospital stay
ranged between 35 and 76 days (mean was 51±14 days). In 8 patients (73%), tumor recurrence was observed and liver metastasis was dominant. These 8 patients died of cancer recurrence. Compared between diseases, the survival period in patients with gallbladder cancer (12±1 months) tended to be shorter than that in patients with biliary malignancies (19±11 months) (p=0.15). Three patients with bile duct cancers survived without tumor relapse at 15, 12, and 12 months at this stage.

DISCUSSION

Nowadays, aggressive surgical exploration for hepatobiliary malignancy combined with hepatic resection and pancreaticoduodenectomy is performed (1-4). However, the usefulness of such an aggressive approach remains controversial because highly advanced tumors are dominant in such cases (13). As the techniques and perioperative management have improved remarkably, our group has actively performed HPD for complete tumor resections (R0) during the last decade. Based on previous reports, the usefulness of HPD has been mainly reported by Japanese surgeons since the 1990s (1-4, 7, 8). This operative procedure is usually performed for bile duct carcinoma and gallbladder carcinoma (1-8). In our series, bile duct carcinoma was dominant. One ampullar carcinoma extended to the hilar bile duct by skip infiltration, which has not been reported previously. Widely intramural extensions of bile duct carcinoma between intra-hepatic bile duct and intra-pancreatic bile duct can be completely resected by HPD (8, 14-16), which is the best indication of this procedure. Other indications are direct invasion or
lymph node metastasis around the pancreatic head of gallbladder carcinoma (8, 15-17). In these indications, the usefulness of PD for lymphadenectomy was still limited (18). In the advanced stages of gall bladder carcinomas, extended surgical resection might provide a survival benefit, based on recent reports (15, 19, 20). In our series, 3 patients with gall bladder carcinomas underwent HPD for lymphadenectomy; however, tumor recurrence in the liver and lymph node were observed early on.

In the present series, right hepatectomy with caudate lobe resection was performed for bile duct carcinoma in 5 patients. HPD with right hepatectomy might be risky for post-operative hepatic failure because of a large volume of resection (21). In such cases, preoperative portal vein embolization might prevent such a lethal complication (22, 23). By applying this technique, we can safely perform HPD with right hepatectomy at present.

In the present series, pylorus preserving PD was mainly performed. Pylorus preserving PD is physiologically better for post-operative nutrition than the usual Whipple’s procedure (24). For the purpose of lymphadenectomy, Whipple’s operation should not be necessary in many cases because peri-pancreatic head lymph node dissection is preferred over peri-pylorus lymph node dissection in biliary malignancies (25). In 3 patients with Whipple’s operation, enlarged lymph nodes were observed at peri-pylorus lesions, and metastasis was suspected in 1 case, and ischemia of the duodenum near the pylorus was remarkable in 2 cases. Operating time and blood loss gradually improved by improvement of surgical techniques in our series. However, HPD is still a high level operation in the upper abdomen. HPD was performed to accomplish curative operation;
however, 3 patients showed curability C. Unexpected wide extension of intramural carcinoma in the intrahepatic bile duct was found in these cases, even after HPD was performed. In cases with remnant cancer cells at surgical cut end of the bile duct, additional local treatment is necessary to avoid tumor relapse. In 2 patients, photodynamic therapy, which is a cancer-specific treatment (26), was performed after the operation. As a result, local tumor recurrence has not been observed in these patients.

Post-operative complications were observed in 4 patients, but the complications were not severe, and there were no hospital stay deaths. Morbidity and mortality rates were still high, particularly in cases with combined vascular resections at this stage (4, 8, 15, 16, 27). Hospital stay was longer than in patients undergoing other abdominal surgeries. To tolerate such an aggressive operation, the indication of HPD should be carefully considered and selected (8). With respect to long-term prognosis, tumor relapse was frequent even after the aggressive resections, particularly in gall bladder carcinomas, in the present series. The usefulness of PD for lymphadenectomy in gall bladder carcinomas was reported (20); however, locally advanced carcinomas, such as cases accompanied with bile duct infiltration, might be avoided because of extremely poor prognoses (28). On the other hand, longer prognosis would be expected in bile duct carcinomas with wide extension by complete and aggressive resection (16, 29).

In conclusion, major surgical resection with simultaneous hepatic resection and pancreaticoduodenectomy (HPD) was performed in 11 patients with biliary malignancies at a single cancer center over the past 10 years. HPD could be safely performed because of
low morbidity rate and no mortality at this stage. In patients with bile duct and ampullar
cancer, long-term survival could be obtained in some cases and, therefore, the indication
of HPD should be considered for widely extensive bile duct cancer. On the other hand, the
indication of HPD for patients with gallbladder cancer with peri-pancreatic lymph node
metastasis should be carefully considered because of early recurrence.

REFERENCES

1. Hirono S, Tani M, Kawai M, Ina S, Uchiyama K, Yamaue H: Indication of
   hepatopancreatoduodenectomy for biliary tract cancer. World J Surg
   2006;30:567-573

2. Aiura K, Shimazu M, Takahashi S, Kitajima M: Clinical evaluation of
   hepatopancreatoduodenectomy (in Japanese with English abstract). Nippon Geka

   Makuuchi M: Indication and outcome of extended right hemihepatectomy combined
   with pancreatoduodenectomy for bile duct carcinoma (in Japanese with English

   S, Muro H: Hepatopancreatoduodenectomy for advanced gallbladder carcinoma.

5. Aldrighetti L, Pulitano C, Arru M, Catena M, Finazzi R, Ferla G:
   "Technological" approach versus clamp crushing technique for hepatic parenchymal

6. Imaizumi T, Hatori T, Tobita K, Fukuda A, Takasaki K, Makuuchi H:
   Pancreateicojejunostomy using duct-to-mucosa anastomosis without a stenting tube. J

7. Takahama T: Post operative complications after hepatopancreatoduodenectomy


<table>
<thead>
<tr>
<th></th>
<th>Age</th>
<th>Gender</th>
<th>Diseases</th>
<th>Reasons for hepatectomy</th>
<th>Reasons for pancreatoduodenectomy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>54</td>
<td>Male</td>
<td>GBC</td>
<td>Hepatic invasion</td>
<td>Lymph node metastasis</td>
</tr>
<tr>
<td>2</td>
<td>69</td>
<td>Male</td>
<td>GBC</td>
<td>Hepatic invasion</td>
<td>Lymph node metastasis</td>
</tr>
<tr>
<td>3</td>
<td>73</td>
<td>Male</td>
<td>BDC</td>
<td>Extension to hilar BD</td>
<td>Extension to intra-pancreatic BD</td>
</tr>
<tr>
<td>4</td>
<td>67</td>
<td>Male</td>
<td>AC</td>
<td>Extension to hilar BD</td>
<td>AC</td>
</tr>
<tr>
<td>5</td>
<td>55</td>
<td>Female</td>
<td>BDC</td>
<td>Extension to hilar BD</td>
<td>Extension to intra-pancreatic BD</td>
</tr>
<tr>
<td>6</td>
<td>71</td>
<td>Female</td>
<td>BDC</td>
<td>Extension to hilar BD</td>
<td>Extension to intra-pancreatic BD</td>
</tr>
<tr>
<td>7</td>
<td>58</td>
<td>Male</td>
<td>BDC</td>
<td>Extension to hilar BD</td>
<td>Extension to intra-pancreatic BD</td>
</tr>
<tr>
<td>8</td>
<td>72</td>
<td>Female</td>
<td>GBC</td>
<td>Hepatic invasion</td>
<td>Lymph node metastasis</td>
</tr>
<tr>
<td>9</td>
<td>69</td>
<td>Male</td>
<td>BDC</td>
<td>Extension to hilar BD</td>
<td>Extension to intra-pancreatic BD</td>
</tr>
<tr>
<td>10</td>
<td>77</td>
<td>Female</td>
<td>BDC</td>
<td>Extension to hilar BD</td>
<td>Extension to intra-pancreatic BD</td>
</tr>
<tr>
<td>11</td>
<td>75</td>
<td>Female</td>
<td>BDC</td>
<td>Extension to hilar BD</td>
<td>Extension to intra-pancreatic BD</td>
</tr>
</tbody>
</table>

GBC; gallbladder cancer, BDC; bile duct cancer, AC; ampullar cancer, BD; bile duct
<table>
<thead>
<tr>
<th>Operation</th>
<th>Operation time (minutes)</th>
<th>Blood loss (ml)</th>
<th>Tumor stage*</th>
<th>Curability*</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD + extended RH</td>
<td>565</td>
<td>2920</td>
<td>IVa</td>
<td>B</td>
</tr>
<tr>
<td>PPPD + resection of segment 4 and 5</td>
<td>615</td>
<td>1892</td>
<td>IVa</td>
<td>A</td>
</tr>
<tr>
<td>PPPD + extended LH</td>
<td>715</td>
<td>910</td>
<td>IVa</td>
<td>B</td>
</tr>
<tr>
<td>PPPD + right lateral sectionectomy</td>
<td>615</td>
<td>2050</td>
<td>IVb</td>
<td>C</td>
</tr>
<tr>
<td>PPPD + extended RH</td>
<td>623</td>
<td>1620</td>
<td>II</td>
<td>B</td>
</tr>
<tr>
<td>PPPD + extended LH</td>
<td>494</td>
<td>2000</td>
<td>III</td>
<td>B</td>
</tr>
<tr>
<td>PPPD + extended RH</td>
<td>695</td>
<td>2500</td>
<td>IVa</td>
<td>C</td>
</tr>
<tr>
<td>PD + resection of segment 4 and 5</td>
<td>730</td>
<td>1000</td>
<td>IVb</td>
<td>B</td>
</tr>
<tr>
<td>PD + extended LH</td>
<td>827</td>
<td>2200</td>
<td>III</td>
<td>B</td>
</tr>
<tr>
<td>PPPD + extended RH</td>
<td>867</td>
<td>950</td>
<td>IVa</td>
<td>C</td>
</tr>
<tr>
<td>PPPD + extended RH</td>
<td>984</td>
<td>1520</td>
<td>IVa</td>
<td>B</td>
</tr>
</tbody>
</table>

PD; pancreatoduodenectomy, PPPD; pylorus preserving pancreatoduodenectomy  
RH; right hepatectomy, LH; left hepatectomy  
* Classification of Biliary Tract Carcinoma by the Japanese Society of Biliary Surgery
<table>
<thead>
<tr>
<th>Complications</th>
<th>Hospital stay (days)</th>
<th>Tumor recurrence</th>
<th>Prognosis (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Pancreatic fistula</td>
<td>76</td>
<td>Liver</td>
<td>Cancer death (12)</td>
</tr>
<tr>
<td>2 None</td>
<td>35</td>
<td>Liver, lymph node</td>
<td>Cancer death (13)</td>
</tr>
<tr>
<td>3 Pancreatic fistula</td>
<td>47</td>
<td>Liver</td>
<td>Cancer death (29)</td>
</tr>
<tr>
<td>4 None</td>
<td>33</td>
<td>Liver, lung</td>
<td>Cancer death (32)</td>
</tr>
<tr>
<td>5 None</td>
<td>41</td>
<td>Liver</td>
<td>Cancer death (35)</td>
</tr>
<tr>
<td>6 None</td>
<td>41</td>
<td>Local recurrence</td>
<td>Cancer death (9)</td>
</tr>
<tr>
<td>7 None</td>
<td>58</td>
<td>Peritoneum</td>
<td>Cancer death (13)</td>
</tr>
<tr>
<td>8 None</td>
<td>47</td>
<td>Liver</td>
<td>Cancer death (11)</td>
</tr>
<tr>
<td>9 None</td>
<td>56</td>
<td>None</td>
<td>Survive (15)</td>
</tr>
<tr>
<td>10 Delayed gastric empty</td>
<td>58</td>
<td>None</td>
<td>Survive (12)</td>
</tr>
<tr>
<td>11 Abscess, Liver failure</td>
<td>69</td>
<td>None</td>
<td>Survive (12)</td>
</tr>
</tbody>
</table>

Table 3. Patient outcomes